首页 > 市场调查报告书 > 医疗设备

体外诊断癌症癌症诊断

市场调查报告书

商品编码

1533606

癌症诊断市场规模、份额和成长分析：按产品、技术、应用、最终用户和地区划分 - 产业预测，2024-2031 年

Cancer Diagnostics Market Size, Share, Growth Analysis, By Product, By Technology, By Application, By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年08月06日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

癌症诊断市场价值将于 2022 年达到 1,123 亿美元，高于 2023 年的 1,200.4 亿美元，预测期内（2024-2031 年）复合年增长率为 6.89%，到 2031 年将达到 2,045.5 亿美元。美元。

癌症诊断涉及识别不同的细胞类型、蛋白质和癌性肿瘤存在的指标。该行业的成长是由全球癌症发病率上升、早期检测意识增强、癌症研究和开发资金增加、诊断测试技术进步以及私人诊断中心数量增加所推动的。根据SkyQuest的详细分析，预计2024年将出现约2,001,140名新癌症患者，将对癌症诊断市场产生直接影响。此外，医疗支出的增加和政府的支持措施也促进了市场的成长。然而，高资本成本、高辐射暴露可能性以及缺乏熟练专业人员等挑战也会影响市场。由于医疗基础设施的改善和政府促进癌症筛检的努力，亚太地区等新兴地区正在经历快速成长。此外，远端医疗和行动医疗应用程式等数位健康技术的采用正在增强远端监控和个人化护理。然而，高成本、监管挑战和资料隐私问题仍然是充分挖掘市场潜力需要解决的主要挑战。

市场概况
消耗品
- 抗体
- 套件/试剂
- 探测
- 其他消耗品
装置
- 病理学设备
玻片染色系统
组织处理系统
细胞处理器
PCR设备
NGS设备
微阵列
其他基于病理学的设备
- 影像设备
CT系统
超音波系统
核磁共振系统
乳房X光摄影系统
核子造影系统
- 切片检查仪器

全球癌症诊断市场：依技术分类

市场概况
体外诊断测试
- 聚合酵素链锁反应
- 原位杂合反应
- 免疫组织化学
- 次世代定序
- 免疫检测
- 微阵列
- 流式细胞技术
- 其他体外诊断技术
成像技术
- 磁振造影
- 电脑断层扫描
- 核子造影
- 乳房X光照相术
- 超音波
切片检查

全球癌症诊断市场：依应用分类

市场概况
乳癌
肺癌
大肠直肠癌
恶性黑色素瘤
其他癌症

全球癌症诊断市场：依最终用户分类

市场概况
医院
诊断实验室
其他的

全球癌症诊断市场规模：按地区划分

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Abbott Laboratories（US）
Agilent Technologies（US）
Becton, Dickinson and Company（BD）（US）
bioMerieux SA（France）
Danaher Corporation（US）
F. Hoffmann-La Roche Ltd.（Switzerland）
GE Healthcare（US）
Hologic, Inc.（US）
Illumina, Inc.（US）
Koninklijke Philips NV（Netherlands）
Merck KGaA（Germany）
Myriad Genetics, Inc.（US）
QIAGEN NV（Netherlands）
Siemens Healthineers AG（Germany）
Sysmex Corporation（Japan）
Thermo Fisher Scientific Inc.（US）
Exact Sciences Corporation（US）
Guardant Health, Inc.（US）
Caris Life Sciences（US）
Foundation Medicine, Inc.（US）

简介目录

Product Code: SQMIG35J2078

Cancer Diagnostics Market was valued at USD 112.3 Billion in 2022 and is expected to rise from USD 120.04 Billion in 2023 to reach a value of USD 204.55 Billion by 2031, at a CAGR of 6.89% during the forecast period (2024-2031).

Cancer diagnostics involves identifying various cell types, proteins, and indicators that signal the presence of cancerous tumors. The growth in this field is largely driven by the increasing global incidence of cancer, heightened awareness of early detection, increased funding for cancer research and development, technological advancements in diagnostic testing, and a rise in private diagnostic centers. According to SkyQuest's detailed analysis, around 2,001,140 new cancer cases are expected in 2024, which will have a direct impact on the cancer diagnostics market. Furthermore, rising healthcare expenditure and supportive government initiatives are contributing to market growth. Despite this, challenges such as significant capital costs, potential high radiation exposure, and a shortage of skilled professionals also affect the market. Emerging regions like Asia-Pacific are experiencing rapid growth due to improvements in healthcare infrastructure and government initiatives promoting cancer screening. Additionally, the adoption of digital health technologies, including telemedicine and mobile health apps, is enhancing remote monitoring and personalized care. However, high costs, regulatory challenges, and data privacy concerns remain major issues to address in order to fully leverage the market potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Diagnostics Market Segmental Analysis

The cancer diagnostics market is segmented based on the Product, Technology, Application, End User and region. Based on the Product, the cancer diagnostics market is segmented into Consumables (Antibodies, Kits & Reagents, Probes, Others) and Instruments (Pathology-Based Instruments [Slide Staining Systems, Tissue Processing Systems, Cell Processors, PCR Instruments, NGS Instruments, Microarrays, Others], Imaging Instruments [CT Systems, Ultrasound Systems, MRI Systems, Mammography Systems, Nuclear Imaging Systems], Biopsy Instruments). Based on the Application, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, and Others. Based on the Technology, the market is segmented into IVD Testing (Polymerase Chain Reaction, In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing, Immunoassay, Microarray, Flow Cytometry, Others), Imaging Technologies (Magnetic Resonance Imaging, Computed Tomography, Nuclear Imaging, Mammography, Ultrasound), and Biopsies. Based on the End User, the market is segmented into Hospitals, Diagnostic Laboratories, Others. Based on Region it is categorized into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa.

Drivers of the Global Cancer Diagnostics Market

Growing government initiatives to promote the benefits of early diagnosis are expected to drive significant growth in the cancer diagnostics market in the near future. In developing and underdeveloped regions, awareness and availability of cancer diagnostic products are relatively low. To address this issue, both private and government organizations are launching awareness campaigns to educate the public about the importance of early diagnosis.

Restraints in the Global Cancer Diagnostics Market

Exposure to radiation from CT scans and X-rays poses health risks, including an increased likelihood of developing serious conditions such as cancer. These potential side effects can lead to decreased patient compliance and acceptance of radiation therapy, which may, in turn, impact the overall use of radiation in cancer diagnosis and treatment.

Market Trends of the Global Cancer Diagnostics Market

The interest in early cancer detection through simple blood tests, known as liquid biopsies, is rapidly growing. These tests offer a less invasive alternative to traditional diagnostic methods and have been gaining traction for their potential to identify cancer at an early stage. Recent research indicates that blood tests, which analyze various markers including genes and proteins, could be sensitive enough to diagnose cancer. This emerging diagnostic approach holds promise for improving early detection and potentially enhancing treatment outcomes.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Supply Chain Analysis
Patent Analysis
Trade Analysis
Ecosystem of the Market
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Global Cancer Diagnostic Market by Product

Market Overview
Consumables
- Antibodies
- Kits & Reagents
- Probes
- Other Consumables
Instruments
- Pathology-Based Instruments
Slide Staining Systems
Tissue Processing Systems
Cell Processors
PCR Instruments
NGS Instruments
Microarrays
Other Pathology-Based Instruments
- Imaging Instruments
CT Systems
Ultrasound Systems
MRI Systems
Mammography Systems
Nuclear Imaging Systems
- Biopsy Instruments

Global Cancer Diagnostic Market By Technology

Market Overview
IVD Testing
- Polymerase Chain Reaction
- In Situ Hybridization
- Immunohistochemistry
- Next-Generation Sequencing
- Immunoassay
- Microarray
- Flow Cytometry
- Other IVD Technologies
Imaging Technologies
- Magnetic Resonance Imaging
- Computed Tomography
- Nuclear Imaging
- Mammography
- Ultrasound
Biopsies

Global Cancer Diagnostic Market By Application

Market Overview
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Other Cancers

Global Cancer Diagnostic Market By End User

Market Overview
Hospitals
Diagnostic Laboratories
Others

Global Cancer Diagnostic Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Koninklijke Philips N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caris Life Sciences (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Foundation Medicine, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments